Sutro Biopharma (NASDAQ:STRO) Upgraded at Wall Street Zen

Key Points

• Sutro Biopharma was upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, while other analysts maintained a mix of ratings including "neutral" and "underperform."
• The company has reported a negative EPS of ($0.14), exceeding consensus estimates, with revenues significantly surpassing expectations at $63.74 million for the quarter.
• Sutro Biopharma holds a market cap of $67.77 million, with a current consensus rating of "Hold" and an average target price of $6.11.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

STRO has been the topic of a number of other research reports. Piper Sandler upgraded shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price objective on the stock in a research note on Monday, June 16th. HC Wainwright restated a "neutral" rating and set a $2.00 price objective on shares of Sutro Biopharma in a research report on Tuesday, April 29th. Finally, Bank of America dropped their price objective on shares of Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating for the company in a report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Sutro Biopharma presently has an average rating of "Hold" and a consensus target price of $5.97.

Sutro Biopharma Trading Up 1.1%

STRO stock traded up $0.01 on Friday, hitting $0.79. The company had a trading volume of 77,375 shares, compared to its average volume of 1,285,453. Sutro Biopharma has a 12-month low of $0.52 and a 12-month high of $5.17. The stock's 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.02. The stock has a market cap of $67.14 million, a price-to-earnings ratio of -0.31 and a beta of 1.66.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.25. The company had revenue of $63.74 million for the quarter, compared to analysts' expectations of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. Research analysts forecast that Sutro Biopharma will post -2.92 earnings per share for the current year.

Institutional Trading of Sutro Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in STRO. Suvretta Capital Management LLC raised its stake in shares of Sutro Biopharma by 3.8% during the fourth quarter. Suvretta Capital Management LLC now owns 7,462,495 shares of the company's stock valued at $13,731,000 after purchasing an additional 275,000 shares in the last quarter. RA Capital Management L.P. purchased a new position in Sutro Biopharma during the 1st quarter valued at about $2,885,000. Acadian Asset Management LLC grew its stake in Sutro Biopharma by 78.9% during the 1st quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company's stock valued at $2,037,000 after acquiring an additional 1,382,661 shares in the last quarter. Vestal Point Capital LP grew its stake in Sutro Biopharma by 1.2% during the 1st quarter. Vestal Point Capital LP now owns 2,600,000 shares of the company's stock valued at $1,692,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its stake in shares of Sutro Biopharma by 0.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,727,925 shares of the company's stock valued at $3,179,000 after buying an additional 11,793 shares in the last quarter. Institutional investors own 96.99% of the company's stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.